State Board of Administration of Florida Retirement System Acquires Shares of 4,635 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

State Board of Administration of Florida Retirement System purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,635 shares of the company’s stock, valued at approximately $255,000.

Other institutional investors and hedge funds have also modified their holdings of the company. IFP Advisors Inc grew its stake in Harmony Biosciences by 49.8% during the third quarter. IFP Advisors Inc now owns 999 shares of the company’s stock worth $45,000 after buying an additional 332 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Harmony Biosciences by 6.2% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 7,502 shares of the company’s stock worth $366,000 after purchasing an additional 437 shares during the last quarter. KBC Group NV raised its holdings in Harmony Biosciences by 22.9% during the 3rd quarter. KBC Group NV now owns 2,461 shares of the company’s stock worth $109,000 after purchasing an additional 458 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Harmony Biosciences by 5.7% during the 3rd quarter. ProShare Advisors LLC now owns 8,673 shares of the company’s stock worth $384,000 after buying an additional 467 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in shares of Harmony Biosciences by 39.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,938 shares of the company’s stock worth $86,000 after buying an additional 549 shares during the period. 84.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HRMY has been the topic of a number of analyst reports. Cantor Fitzgerald lifted their price objective on shares of Harmony Biosciences from $71.00 to $75.00 in a report on Wednesday, May 3rd. The Goldman Sachs Group lowered their target price on Harmony Biosciences from $49.00 to $43.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 22nd. TheStreet cut Harmony Biosciences from a “b-” rating to a “c” rating in a research note on Tuesday, February 21st. Bank of America initiated coverage on Harmony Biosciences in a research note on Thursday, April 20th. They set a “neutral” rating on the stock. Finally, Mizuho reiterated a “buy” rating and set a $60.00 target price on shares of Harmony Biosciences in a research note on Wednesday, March 29th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Harmony Biosciences has a consensus rating of “Moderate Buy” and an average price target of $62.89.

Harmony Biosciences Stock Performance

Shares of NASDAQ:HRMY opened at $35.01 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 4.90 and a quick ratio of 4.85. The business’s 50 day moving average price is $35.23 and its 200-day moving average price is $46.25. The firm has a market capitalization of $2.10 billion, a PE ratio of 11.29, a P/E/G ratio of 0.52 and a beta of 0.45. Harmony Biosciences Holdings, Inc. has a 1 year low of $29.81 and a 1 year high of $62.08.

Harmony Biosciences (NASDAQ:HRMY – Get Rating) last posted its earnings results on Tuesday, February 21st. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.47. The company had revenue of $128.31 million for the quarter, compared to the consensus estimate of $127.73 million. Harmony Biosciences had a return on equity of 49.67% and a net margin of 40.19%. As a group, equities research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.4 earnings per share for the current fiscal year.

Harmony Biosciences Company Profile

(Get Rating)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.